Alkermes plc (NASDAQ:ALKS) Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. reduced its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 41.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 163,581 shares of the company’s stock after selling 115,471 shares during the quarter. Capital Fund Management S.A. owned approximately 0.10% of Alkermes worth $4,705,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in ALKS. CIBC Asset Management Inc increased its position in shares of Alkermes by 4.4% during the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock worth $263,000 after purchasing an additional 384 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in shares of Alkermes by 3.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company’s stock valued at $408,000 after acquiring an additional 532 shares during the period. Sei Investments Co. grew its position in shares of Alkermes by 1.1% during the fourth quarter. Sei Investments Co. now owns 75,394 shares of the company’s stock worth $2,168,000 after acquiring an additional 828 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Alkermes by 106.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after acquiring an additional 842 shares during the period. Finally, Venturi Wealth Management LLC purchased a new stake in Alkermes in the 4th quarter valued at $25,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Stock Up 1.5 %

ALKS opened at $27.00 on Monday. The company has a 50 day moving average of $33.14 and a two-hundred day moving average of $30.47. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45. The company has a market cap of $4.45 billion, a P/E ratio of 12.44, a P/E/G ratio of 2.20 and a beta of 0.39.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Research analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group increased their target price on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and lifted their target price for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft upped their price target on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, HC Wainwright restated a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.